Guangzhou Baiyunshan Pharmaceutical Holdings approved amendments to its “Rules of Procedures for the Nomination and Remuneration Committee of the Board of Directors” at the 30th meeting of the 9th session of its board on 28 October 2025. The rules aim to enhance the company’s governance structure by standardizing nomination, appointment, and evaluation procedures for directors and senior management.

Key updates include the committee’s composition, with a majority of independent non-executive directors and at least one director of a different gender, encompassing a five-member group responsible for formulating competency profiles, recommending appointments, and overseeing remuneration policies. The rules also outline the nomination process, which involves identifying suitably qualified candidates, assessing individuals’ independence, and setting performance-based criteria to ensure an effective and transparent appointment framework.

Additional measures address the board’s diversity policy, including gender, educational, and cultural factors, to refine the overall structure. The rules detail meeting requirements, voting procedures, and confidentiality obligations to support transparent governance. These amendments seek to align the committee’s work with applicable legal and listing regulations, further reinforcing robust oversight of directors and senior management. The approved measures take effect upon their adoption, as stipulated in the updated document.